Company Sarepta Therapeutics, Inc. Sao Paulo
Equities
S1RP34
BRS1RPBDR005
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.25 BRL | +0.21% | -2.52% | +44.82% |
Business Summary
Number of employees: 1,314
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
RNA-targeted Therapeutics, Gene Therapy and Other Genetic Therapeutic Modalities
100.0
%
| 933 | 100.0 % | 1,243 | 100.0 % | +33.26% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 933 | 100.0 % | 1,243 | 100.0 % | +33.26% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 26/17/26 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 01/15/01 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 48 | 01/18/01 | |
Will Tilton
HRO | Human Resources Officer | - | - |
Alison Nasisi
HRO | Human Resources Officer | - | - |
Dallan Murray
PRN | Corporate Officer/Principal | - | 01/13/01 |
Diane Berry
PRN | Corporate Officer/Principal | - | 01/11/01 |
Ryan Brown
LAW | General Counsel | 46 | 01/18/01 |
Joseph Bratica
AUD | Comptroller/Controller/Auditor | 60 | 01/17/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 26/17/26 |
M. Wilsey
CHM | Chairman | 71 | 31/09/31 |
Richard Barry
BRD | Director/Board Member | 65 | 02/15/02 |
Director/Board Member | 86 | 01/10/01 | |
Stephen Mayo
BRD | Director/Board Member | 62 | 16/21/16 |
Claude Nicaise
BRD | Director/Board Member | 71 | 02/15/02 |
Michael Chambers
BRD | Director/Board Member | - | 02/22/02 |
Kathryn Boor
BRD | Director/Board Member | 65 | 02/22/02 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 94,523,766 | 89,825,408 ( 95.03 %) | 0 | 95.03 % |
Company contact information
Sarepta Therapeutics, Inc.
215 First Street Suite 415
02142, Cambridge
+617 274 4000
http://www.sareptatherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-0.67% | 21.97B | |
-4.64% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+13.63% | 7.76B |
- Stock Market
- Equities
- SRPT Stock
- S1RP34 Stock
- Company Sarepta Therapeutics, Inc.